[A15-58] Nivolumab - Addendum to Commission A15-32
Last updated 05.02.2016
Commission awarded on 22.12.2015 by the Federal Joint Committee (G-BA).
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A18-40||Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)||Commission completed|
|A15-32||Nivolumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)||Commission completed|